Back to discover
Disease
Anhedonia
Late-stage therapeutic developmentEmerging research
2
Publications
14
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-11-29The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Ketamine induced synaptic plasticity operates independently of long-term potentiation.
Research2024-06-19Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q4 2026.
- 2 industry developments reported.
Upcoming Milestones
- Q4 2026Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis
- Q1 2027Dopaminergic Therapy for Inflammation-Related Anhedonia in Depression - 2
- Q4 2027The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIV
- Q4 2027Vagus Nerve Stimulation and Approach-Avoidance Behavior in Anhedonia and Anxiety
- Q2 2028Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial
Major developments
Major trial resultsHigh impact
Results posted2026-03-17
Upcoming trial readoutHigh impact
Results expected Q4 20262026-04-29
Clinical MilestonesView all 10Hide
Results posted
- 2026-03-17Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) StudyResults posted
- 2026-02-13A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyResults posted
Results expected
- 2026-06-08A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseResults expected Q1 2030
- 2026-05-28The Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIVResults expected Q4 2027
- 2026-04-29Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and PsychosisResults expected Q4 2026
- 2026-04-23Vagus Nerve Stimulation and Approach-Avoidance Behavior in Anhedonia and AnxietyResults expected Q4 2027
- 2026-03-24Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging TrialResults expected Q2 2028
Recently completed
+2 more in the activity timeline below
Industry & MarketViewHide
- 2026-09-17<![CDATA[Embodied Technologies for Mental Health: Leveraging Synthetic Emotions for Dissociation and Anhedonia]]>Industry · Psychiatric Times
- 2026-09-03<![CDATA[Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia]]>Industry · Psychiatric Times
Activity timeline12
- 2026-09-17Industry<![CDATA[Embodied Technologies for Mental Health: Leveraging Synthetic Emotions for Dissociation and Anhedonia]]>Industry · Psychiatric Times
- 2026-09-03Industry<![CDATA[Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia]]>Industry · Psychiatric Times
- 2026-06-08ClinicalA Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseResults expected Q1 2030
- 2026-05-28ClinicalThe Role of Inflammation in Central Nervous System (CNS) Mechanisms of Anhedonia and Psychomotor Slowing in Depressed People With HIVResults expected Q4 2027
- 2026-05-08ClinicalEffects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot TrialCompleted
- 2026-04-29ClinicalExamining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and PsychosisResults expected Q4 2026
- 2026-04-23ClinicalVagus Nerve Stimulation and Approach-Avoidance Behavior in Anhedonia and AnxietyResults expected Q4 2027
- 2026-03-24ClinicalElucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging TrialResults expected Q2 2028
- 2026-03-17ClinicalAnhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) StudyResults posted
- 2026-02-13ClinicalA Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
14
6
7
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes8
- Hippocampus2
- Antidepressive Agents1
- Behavior, Animal1
- Corticosterone1
- Depression1
- Ketamine1
- Long-Term Potentiation1
- Neuronal Plasticity1
Leading journals2
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology1
- The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry1
Leading researchers8
- Gu J1
- Kavalali ET1
- Li M1
- Liu H1
- Maes M1
- Monteggia LM1
- Piazza MK1
- Xu G1
Affiliations (unnormalised)6
- Anhui Provincial Key Laboratory for Brain Bank Construction and Resource Utilization1
- Chaohu Hospital of Anhui Medical University1
- Key Laboratory of Psychosomatic Medicine1
- Sichuan Provincial Center for Mental Health1
- The Second People's Hospital of Huizhou1
- Vanderbilt Brain Institute1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Inability to experience pleasure due to impairment or dysfunction of normal psychological and neurobiological mechanisms. It is a symptom of many PSYCHOTIC DISORDERS (e.g., DEPRESSIVE DISORDER, MAJOR; and SCHIZOPHRENIA).
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.